Comparison of clinico-pathological characteristics and survival of recurrent ovarian cancer patients on seven different chemo-protocols

Publié en ligne: 07 déc. 2018

Pages: 87 - 97

Accepté: 16 juil. 2018

DOI: https://doi.org/10.2478/acph-2019-0002

Mots clés

ovarian cancer, carboplatin plus paclitaxel, topotecan, bevacizumab, docetaxel

© 2019 Saima Sattar et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.